Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
Intercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence of potential" in patients with severe alcohol-associated hepatitis ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · IT
- [CONFLICT] Share of people in Europe with unfavorable opinion on the Roma People
- [CONFLICT] 'In a better place but not 100%' - Raducanu out of Rome as wait for return continues
- [DIPLOMACY] After more Trump criticisms of pontiff, Italy’s foreign minister says attacks on Pope Leo ‘not acceptable’
- [HEALTH] "Improved Me Quite A Bit": Giorgia Meloni Calls Out Viral Fake Lingerie Photo
- [TECH] Italy PM Meloni warns over AI deepfakes after false photos of her circulate
- [CONFLICT] Zeynep Sönmez Roma Açık'ta 2. tura yükseldi